I think SPPI's physician loyalty argument is hogwash. If there was a steady supply of generic leuvo, docs would leave Fusilev for good.
The only reason they might keep this revenue is because generic leuvo prices are set so low, no real incentive for generic manufacturers to bring them back esp if the FDA is going to make them jump thru a lot of hoops.